Taysha and Catalent Expand Partnership for TSHA-102 Manufacturing Support
Taysha Gene TherapiesSigSignificance2.60SenSentiment+4.47EnvEnvironment0.00SocSocial+2.42GovGovernance+0.73
Rett syndrome progresses through early stagnation, regression, plateau and late motor deterioration, with MECP2 mutations affecting 15,000–20,000 patients in the U.S., EU and U.K. TSHA-102, Taysha’s AAV gene therapy candidate, targets the genetic root cause, where no approved disease-modifying options exist. Taysha and Catalent expand their strategic partnership to secure long-term commercial manufacturing capacity and scalable supply for TSHA-102 at Catalent’s nearly 40 global sites.
Coverage (2)
- Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome (finance.yahoo.com)
- Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome (globenewswire.com)